Clinical trials are now exploring CDK4/6 inhibitors, EZH2 inhibitors, and immune checkpoint inhibitors in genetically defined subgroups, with early data suggesting potential synergy in tumors with specific epigenetic signatures (Reuss et al., 2020
But we need to ask the tough questions: Effect Size: Is a 1-2% increase in BMD, even if statistically significant, enough to make a clinical difference in fracture risk
By activating GLP-1 receptors, semaglutide helps control blood sugar levels and supports weight loss, which can indirectly improve cholesterol levels
doi:10.3892/etm.2020.9557 Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D
Revitalizing ancient mitochondria with nano-strategies: mitochondria-remedying nanodrugs concentrate on disease control
Case report: Semaglutide-associated depression: a report of two cases